The joint venture set up by Novartis and Qualcomm has teamed up with Lux Capital to funnel $6.5 million into Science 37. Los Angeles, CA-based Science 37 will use the cash to step up the expansion of its virtual, tech-enabled model of clinical trial services.
Johnson & Johnson has added another company to its ever-growing network of third-party drug discovery allies. The latest deal sees J&J subsidiary Janssen Biotech follow GlaxoSmithKline, Merck, Novartis and others by hooking up with Nuevolution to get a look at its drug discovery platform.
Novartis, developing cancer treatments that tap the power of the immune system, signed a pair of agreements to pad its pipeline of new oncology therapies, planning to test them alone and in tandem with in-house assets.
Novartis has come good on its promise to continue collaborating with Gamida Cell despite twice walking away from takeover agreements. The Big Pharma handed over $5 million (€4.4 million) for a 2.5% stake in Gamida Cell this week--and promised to invest a further $10 million if its collaborator wraps up an equity financing by the end of 2017.
This year's Fierce 15 companies are all working on big ideas such as cutting-edge patient monitoring, smartphone-based imaging, biodegradable valves and vessels, more accurate knee implants, intestinal ablation to treat diabetes, energy-delivering angioplasty balloons, an implantable cell-based pancreas replacement, and connected asthma inhalers as well as the consumerization of health devices and diagnostics.
Novartis is acquiring more of stem cell partner Gamida Cell but steering away from buying the company outright as it blueprints a Phase III trial for its blood cancer therapy.
Last week, the U.S. Patent Trial and Appeal Board took a long-term Gilenya patent out of commission, putting the Novartis multiple sclerosis drug in line for early generic competition.
Right now, Novartis' Sandoz has the only biosimilar on the U.S. market. And it's looking to make it two.
A month removed from launching the U.S.'s first biosimilar, Novartis is again setting sights on an Amgen cash cow, lining up for FDA approval with a copy of the blockbuster Enbrel.
Xoma has worked a deal to outlicense a cancer antibody to its longtime partners at Novartis. In the deal Xoma will get $37 million in badly needed cash upfront, some relief on $13.5 million in debt and the chance to earn $480 million in milestones, if all goes as planned.